Table 2.
Medication of the study population.
|
PD patients (n = 1,385) |
Patients with WO (n = 763) | Patients without WO (n = 622) | p | |
|---|---|---|---|---|
| Levodopa-benserazide, n(%)a,$ | 1206 (87.1%) | 680 (89.2%) | 526 (84.6%) | 0.010* |
| Levodopa-cabidopa, n(%)a,$ | 402 (29.0%) | 275 (36.0%) | 127 (20.4%) | <0.001* |
| Pramipexole, n(%)a,$ | 587 (42.4%) | 344 (45.1%) | 243 (39.1%) | 0.024* |
| Piribedil, n(%)a,$ | 261 (18.8%) | 147 (19.3%) | 114 (18.3%) | 0.657 |
| Bromocriptine, n(%)a,$ | 5 (0.4%) | 3 (0.4%) | 2 (0.3%) | 0.825 |
| Rasagiline, n(%)a,$ | 22 (1.6%) | 13 (1.7%) | 9 (1.4%) | 0.704 |
| Selegiline, n(%)a,$ | 227 (16.4%) | 136 (17.8%) | 91 (14.6%) | 0.110 |
| Trihexyphenidyl | 86 (6.2%) | 50 (6.6%) | 36 (5.8%) | 0.557 |
| Amantadine, n(%)a,$ | 128 (9.2%) | 89 (11.7%) | 39 (6.3%) | 0.001* |
| Entacapone, n(%)a,$ | 15 (1.1%) | 10 (1.3%) | 5 (0.8%) | 0.440 |
| Numbers of medications | 2 (1, 3) | 2 (2, 3) | 2 (1, 2) | <0.001* |
| Medical treatment strategies, n(%)a,$ | <0.001* | |||
| Levodopa monotherapy | 390 (28.2%) | 185 (24.2%) | 205 (33.0%) | |
| Levodopa plus other drugs | 902 (65.1%) | 541 (70.9%) | 361 (58.0%) | |
| DA monotherapy | 77 (5.6%) | 28 (3.7%) | 49 (7.9%) | |
| Non-dopaminergic treatment | 16 (1.2%) | 9 (1.2%) | 7 (1.1%) |
WO, Wearing-off; DA, dopamine agonist.
a
Presented as number(percentage).
$
Data were analyzed by χ2 test.
*
p < 0.05 of the comparison between two groups.